Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Biotechs continue attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy pla
-
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
-
The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies.
-
BioNTech SE will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at ASCO 2026.
-
BioNTech SE präsentiert neue klinische Daten und Studienupdates zu Programmen in der spätklinischen Entwicklung sowie zu innovativen Kombinationsprogrammen
-
STORM Therapeutics announces that a subset analysis of sarcoma patients enrolled in the Phase 1 dose escalation study of STC-15 will be presented at ASCO.
-
Autolus announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
-
Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2...
-
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent...